HERON THERAPEUTICS, INC. /DE/ Interest Expense
HERON THERAPEUTICS, INC. /DE/ (HRTX) reported Interest Expense of $3.87 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-12.
Discontinued › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2024-03-12
- HERON THERAPEUTICS, INC. /DE/ interest expense for the quarter ending 2017-03-31 was $1.03M, a 674.44% increase year-over-year.
- HERON THERAPEUTICS, INC. /DE/ interest expense for the quarter ending 2016-12-31 was $1.27M, a 414.17% increase year-over-year.
- HERON THERAPEUTICS, INC. /DE/ interest expense for the quarter ending 2016-09-30 was $886.00K, a 266.12% increase year-over-year.
- HERON THERAPEUTICS, INC. /DE/ interest expense for the quarter ending 2016-06-30 was $257.00K, a 8.44% increase year-over-year.
- HERON THERAPEUTICS, INC. /DE/ interest expense for fiscal 2023 was $3.87M, a 56.35% increase from fiscal 2022.
- HERON THERAPEUTICS, INC. /DE/ interest expense for fiscal 2022 was $2.47M, a 2.66% increase from fiscal 2021.
- HERON THERAPEUTICS, INC. /DE/ interest expense for fiscal 2021 was $2.41M, a 26.78% increase from fiscal 2020.
- HERON THERAPEUTICS, INC. /DE/ interest expense for fiscal 2020 was $1.90M, a 29.14% increase from fiscal 2019.
| Period end | Interest Expense 3 month | Interest Expense 3 month as first filed | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|---|
| 2023-12-31 | $3.87M 10-K · filed 2024-03-12 | ||||
| 2022-12-31 | $2.47M 10-K · filed 2024-03-12 | ||||
| 2021-12-31 | $2.41M 10-K · filed 2023-03-29 | ||||
| 2020-12-31 | $1.90M 10-K · filed 2022-02-28 | ||||
| 2019-12-31 | $1.47M 10-K · filed 2022-02-28 | ||||
| 2018-12-31 | $2.67M 10-K · filed 2021-02-24 | ||||
| 2017-12-31 | $3.94M 10-K · filed 2020-03-02 | ||||
| 2017-03-31 | $1.03M 10-Q · filed 2017-05-10 | $2.30M derived: sum of 2 quarters · filed 2017-05-10 | $3.19M derived: sum of 3 quarters · filed 2017-05-10 | $3.44M derived: sum of 4 quarters · filed 2017-05-10 | |
| 2016-12-31 | $1.27M 10-K · filed 2017-02-23 | $2.16M derived: sum of 2 quarters · filed 2017-02-23 | $2.41M derived: sum of 3 quarters · filed 2017-02-23 | $2.66M 10-K · filed 2019-02-22 | |
| 2016-09-30 | $886.00K 10-K · filed 2017-02-23 | $1.14M derived: sum of 2 quarters · filed 2017-02-23 | $1.28M derived: sum of 3 quarters · filed 2017-05-10 | $1.52M derived: sum of 4 quarters · filed 2017-05-10 | |
| 2016-06-30 | $257.00K 10-K · filed 2017-02-23 | $390.00K derived: sum of 2 quarters · filed 2017-05-10 | $637.00K derived: sum of 3 quarters · filed 2017-05-10 | $879.00K derived: sum of 4 quarters · filed 2017-05-10 | |
| 2016-03-31 | $133.00K 10-Q · filed 2017-05-10 | $380.00K derived: sum of 2 quarters · filed 2017-05-10 | $622.00K derived: sum of 3 quarters · filed 2017-05-10 | $859.00K derived: sum of 4 quarters · filed 2017-05-10 | |
| 2015-12-31 | $247.00K 10-K · filed 2017-02-23 | $489.00K derived: sum of 2 quarters · filed 2017-02-23 | $726.00K derived: sum of 3 quarters · filed 2017-02-23 | $958.00K 10-K · filed 2018-02-27 | |
| 2015-09-30 | $242.00K 10-K · filed 2017-02-23 | $479.00K derived: sum of 2 quarters · filed 2017-02-23 | $711.00K derived: sum of 3 quarters · filed 2017-02-23 | $938.00K derived: sum of 4 quarters · filed 2017-02-23 | |
| 2015-06-30 | $237.00K 10-K · filed 2017-02-23 | $469.00K derived: sum of 2 quarters · filed 2017-02-23 | $696.00K derived: sum of 3 quarters · filed 2017-02-23 | $920.00K derived: sum of 4 quarters · filed 2017-02-23 | |
| 2015-03-31 | $232.00K 10-K · filed 2017-02-23 | $459.00K derived: sum of 2 quarters · filed 2017-02-23 | $683.00K derived: sum of 3 quarters · filed 2017-02-23 | $903.00K derived: sum of 4 quarters · filed 2017-02-23 | |
| 2014-12-31 | $227.00K 10-K · filed 2016-02-19 | $451.00K derived: sum of 2 quarters · filed 2016-02-19 | $671.00K derived: sum of 3 quarters · filed 2016-02-19 | $887.00K 10-K · filed 2017-02-23 | |
| 2014-09-30 | $224.00K 10-K · filed 2016-02-19 | $444.00K derived: sum of 2 quarters · filed 2016-02-19 | $660.00K derived: sum of 3 quarters · filed 2016-02-19 | $872.00K derived: sum of 4 quarters · filed 2016-02-19 | |
| 2014-06-30 | $220.00K 10-K · filed 2016-02-19 | $436.00K 10-Q · filed 2014-08-04 | $648.00K derived: sum of 3 quarters · filed 2016-02-19 | $857.00K derived: sum of 4 quarters · filed 2016-02-19 | |
| 2014-03-31 | $216.00K 10-K · filed 2016-02-19 | $428.00K derived: sum of 2 quarters · filed 2016-02-19 | $637.00K derived: sum of 3 quarters · filed 2016-02-19 | $842.00K derived: sum of 4 quarters · filed 2016-02-19 | |
| 2013-12-31 | $212.00K 10-K · filed 2015-03-13 | $421.00K derived: sum of 2 quarters · filed 2015-03-13 | $626.00K derived: sum of 3 quarters · filed 2015-03-13 | $828.00K 10-K · filed 2016-02-19 | |
| 2013-09-30 | $209.00K 10-K · filed 2015-03-13 | $414.00K derived: sum of 2 quarters · filed 2015-03-13 | $615.00K derived: sum of 3 quarters · filed 2015-03-13 | ||
| 2013-06-30 | $205.00K 10-K · filed 2015-03-13 | $204.00K 10-Q · filed 2014-08-04 | $405.00K 10-Q · filed 2014-08-04 | ||
| 2013-03-31 | $201.00K 10-Q · filed 2014-05-12 | ||||
| 2012-12-31 | $605.00K 10-K · filed 2015-03-13 | ||||
| 2012-03-31 | $202.00K 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Lite Strategy, Inc. (LITS) | United States | $0.049B |